Journal
BRITISH JOURNAL OF CANCER
Volume 124, Issue 9, Pages 1469-1474Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-020-01233-5
Keywords
-
Categories
Funding
- University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre
- National Institute for Health Research (NIHR) Health Technology Assessment programme [HTA 07/60/49]
- Ninewells Cancer Campaign
- National Health and Medical Research Council
- German Federal Ministry of Education and Research (BMBF) [FKZ 01ZP0508]
- Cancer Research UK
- UCLH Charities
- National Institutes of Health Research (NIHR) [HTA/07/60/49] Funding Source: National Institutes of Health Research (NIHR)
Ask authors/readers for more resources
In the TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) was shown to be non-inferior to whole-breast external beam radiotherapy for local recurrence in breast cancer patients. Long-term outcomes showed no significant differences in breast cancer outcomes, but there were fewer deaths from non-breast cancer causes. It is recommended to consider including TARGIT-IORT in pre-operative consultations with eligible patients.
In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any breast cancer outcome, whereas there were fewer deaths from non-breast-cancer causes. TARGIT-IORT should be included in pre-operative consultations with eligible patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
